Berlin Cures Holding
Berlin Cures Holding AG is a privately held Swiss biotech founded in 2014 that develops aptamer-based therapeutics targeting functional autoantibodies for autoimmune and related diseases, operating pre-commercially from Zug with 11-50 employees.
- Company typePrivate
- Founded2014
- HeadquartersZug, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Berlin Cures Holding does
Berlin Cures Holding AG is a privately held Swiss biotechnology company founded in 2014, headquartered in Zug, Switzerland, with a workforce of 11-50 employees. The company develops aptamer-based therapeutics designed to neutralize functional autoantibodies — disease-driving antibodies implicated in autoimmune and related conditions. Its core scientific proposition is the use of aptamers (short, single-stranded DNA or RNA molecules capable of binding specific molecular targets with high affinity) as a therapeutic modality against pathogenic autoantibodies, positioning it within a niche segment of the autoimmune therapeutics landscape.
The company's business model is consistent with that of a clinical-stage biotech: it is pre-commercial, with no disclosed revenue, customers, or licensing deals in the supplied data. Value creation is expected to come from advancing its aptamer pipeline through clinical development, ultimately seeking partnerships, licensing arrangements, or M&A exit rather than direct product sales. The company is founder-led, with co-founder Marko Bagaric serving on the Board, and it operates with a small, specialized team typical of platform-discovery-stage biotechs.
Data on funding history, partnerships, product pipeline specifics, clinical trial status, IP portfolio, and go-to-market mechanics is absent from the supplied source material. The single identifiable source does not relate substantively to Berlin Cures Holding, so the strategic, financial, and operational profile above is reconstructed solely from the firmographic baseline and should be treated as a thin-data snapshot rather than a fully validated investment profile.
Berlin Cures Holding firmographics
Firmographics- Name
- Berlin Cures Holding
- Website
- https://berlincures.ch
- Company type
- Private
- Founded year
- 2014
- Headcount range
- 11–50 employees
- Short description
- Berlin Cures Holding AG is a privately held Swiss biotech founded in 2014 that develops aptamer-based therapeutics targeting functional autoantibodies for autoimmune and related diseases, operating pre-commercially from Zug with 11-50 employees.
- Ownership category
- akta.pro rank
Berlin Cures Holding industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
- akta.pro secondary industry
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
Keywords
Where Berlin Cures Holding is headquartered
LocationHeadquarters
- HQ city
- Zug
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
Berlin Cures Holding business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Berlin Cures Holding product offering
Product offeringCore offering
Berlin Cures Holding AG develops aptamer-based therapeutics designed to target and neutralize functional autoantibodies that drive certain chronic and autoimmune diseases. The company's work centers on discovering and optimizing single-stranded nucleic acid aptamers as drug candidates, with its lead programs focused on indications linked to pathogenic autoantibody activity.
Differentiator
Problem solved
Functional benefit
Products and services
- Aptamer-based therapeutic pipeline (functional autoantibody targeting)
Companies that use Berlin Cures Holding
Customer profileIdeal customer profiles1 record
Berlin Cures Holding technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Berlin Cures Holding partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Berlin Cures Holding competitors and assessment
Company assessmentEmerging players
- Aptamer Group: UK-based developer of aptamer-based technology for therapeutics and diagnostics. Comparable on the underlying aptamer discovery and selection platform, though currently more diagnostics/partnering-focused than Berlin Cures' therapeutic positioning.
- MorphoSys: Biopharma developing antibody-based therapeutics for autoimmune and inflammatory diseases. Comparable on therapeutic modality (engineered antibodies) and on indication focus, though larger and now under Novartis.
Direct peers
- argenx: Commercial-stage biotech developing FcRn-modulating antibody therapeutics for autoimmune diseases (e.g., myasthenia gravis, CIDP). Directly comparable to Berlin Cures on autoimmune disease focus and on developing therapeutics that neutralize pathogenic antibody activity.
- UCB: Global biopharma with a deep immunology franchise (e.g., rozanolixizumab, an FcRn antibody) targeting autoimmune diseases driven by pathogenic antibodies. Closely aligned with Berlin Cures on indication space and mechanism targeting.
- Annexon Biosciences: Clinical-stage biotech developing therapeutics that inhibit the classical complement pathway to address antibody-mediated autoimmune diseases. Directly comparable on the mechanism of neutralizing pathogenic autoantibody-driven pathology.
Broad incumbents
- Sanofi: Global pharma with one of the largest immunology and rare disease franchises (Dupixent, rilzabrutinib). Comparable on indication focus and commercial scale in autoimmune therapeutics.
- Novartis: Swiss-headquartered global pharma with significant autoimmune and rare disease franchises. Comparable as a large incumbent with overlapping disease focus and as a Swiss-headquartered pharma of strategic interest.
- Horizon Therapeutics (Amgen): Specialty biopharma acquired by Amgen with a focus on rare and autoimmune diseases (e.g., teprotumumab for thyroid eye disease). Comparable as a broad incumbent operating across autoantibody-driven indications.
- Takeda Pharmaceutical: Global pharma with rare disease, immunology, and plasma-derived therapy franchises. Comparable as a broad incumbent addressing antibody-mediated diseases including rare autoimmune indications.
- Roche: Swiss-headquartered global pharma with a major immunology franchise including ocrelizumab and several autoimmune biologics. Comparable as a broad Swiss incumbent in the autoimmune therapeutics space.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Berlin Cures Holding social profiles
Digital presenceBerlin Cures Holding financial estimates
Financial estimateRevenue estimate
Valuation estimate
Berlin Cures Holding leadership team
Management profileNumber of profiles
Profiles1 record
Berlin Cures Holding funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Berlin Cures Holding M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Berlin Cures Holding
What does Berlin Cures Holding do?
Berlin Cures Holding AG develops aptamer-based therapeutics designed to target and neutralize functional autoantibodies that drive certain chronic and autoimmune diseases. The company's work centers on discovering and optimizing single-stranded nucleic acid aptamers as drug candidates, with its lead programs focused on indications linked to pathogenic autoantibody activity.
When was Berlin Cures Holding founded?
Berlin Cures Holding was founded in 2014. It employs 11 to 50 people.
Where is Berlin Cures Holding based?
Berlin Cures Holding is headquartered in Zug, Switzerland, in the Europe region.
Who are Berlin Cures Holding's main competitors?
Emerging players on record are Aptamer Group and MorphoSys. Direct peers are argenx, UCB and Annexon Biosciences. Broad incumbents are Sanofi, Novartis, Horizon Therapeutics (Amgen), Takeda Pharmaceutical and Roche.
Does Berlin Cures Holding have an API?
No public API is recorded for Berlin Cures Holding.
What industry is Berlin Cures Holding in?
Berlin Cures Holding's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies, with a secondary code of HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 541714 and its SIC code is 2836.